title: Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome.
abstract: BACKGROUND
  The aim of this study was to evaluate the effects of metformin and acarbose on insulin resistance, hormone profiles and ovulation rates in patients with clomiphene citrate-resistant polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Thirty clomiphene citrate-resistant patients were selected randomly and divided into two groups. Group I was treated with 100 mg/day clomiphene citrate and 300 mg/day acarbose 100 mg/day orally, for 3 months. Group II was treated with clomiphene citrate 100 mg/day and metformin 1700 mg/day orally, for 3 months. Serum fasting insulin and glucose, FSH, LH, estradiol, progesterone, prolactin and total testosterone levels plus body mass index (BMI) were measured before and after treatment. Follicle growth was followed by transvaginal ultrasonography.
  
  
  RESULTS
  LH:FSH ratio and total testosterone concentrations decreased (P<0.05) and ovulation rates increased in both groups. Reduction in weight and BMI was only significant in the acarbose group.
  
  
  CONCLUSIONS
  Both treatment modalities were effective in the treatment of insulin resistance and improving ovulation rates. Increase in the number of eumenorrhoeic and normoinsulinaemic cases and decrease in the number of insulin-resistant cases were significant in both groups (P<0.05). Ovulation rate was greater in the metformin group in the second month of therapy (P<0.05). Acarbose was found to be a safe and effective agent that could be used in cases with clomiphene-resistant PCOS.
authors.affiliation: Süleymaniye Maternity and Women's Disease Research and Teaching Hospital, Assisted Reproductive Techniques Unit and Istanbul University, Istanbul, Turkey. suhas@net.net.tr
authors.forename: A S
authors.initials: AS
authors.lastname: Sönmez
authors.forename: L
authors.initials: L
authors.lastname: Yasar
authors.forename: K
authors.initials: K
authors.lastname: Savan
authors.forename: S
authors.initials: S
authors.lastname: Koç
authors.forename: J
authors.initials: J
authors.lastname: Ozcan
authors.forename: A
authors.initials: A
authors.lastname: Toklar
authors.forename: F
authors.initials: F
authors.lastname: Yazicioğu
authors.forename: A
authors.initials: A
authors.lastname: Akgün
authors.forename: N
authors.initials: N
authors.lastname: Sut
mesh_terms: D020909:Acarbose / Q000494:pharmacology*; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002996:Clomiphene / Q000494:pharmacology; D004351:Drug Resistance; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D007986:Luteinizing Hormone / Q000097:blood; D008687:Metformin / Q000494:pharmacology*; D010060:Ovulation / Q000187:drug effects*; D010062:Ovulation Induction / Q000379:methods; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D013739:Testosterone / Q000097:blood
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D002996:Clomiphene; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008687:Metformin; D020909:Acarbose